替格瑞洛:一种治疗老问题的新药。

Andrea Rognoni, Chiara Cavallino, Alessandro Lupi, Gioel G Secco, Alessia Veia, Sara Bacchini, Roberta Rosso, Sandra Brunelleschi, Francesco Rametta, Angelo S Bongo
{"title":"替格瑞洛:一种治疗老问题的新药。","authors":"Andrea Rognoni,&nbsp;Chiara Cavallino,&nbsp;Alessandro Lupi,&nbsp;Gioel G Secco,&nbsp;Alessia Veia,&nbsp;Sara Bacchini,&nbsp;Roberta Rosso,&nbsp;Sandra Brunelleschi,&nbsp;Francesco Rametta,&nbsp;Angelo S Bongo","doi":"10.2174/1574890109666140901150224","DOIUrl":null,"url":null,"abstract":"<p><p>Cardiovascular disease and in particular, acute coronary syndromes are one of the principle causes of death in the industrialized countries. In the setting of acute coronary syndromes (both ST - segment or non ST - segment elevation myocardial infarction), platelets aggregation plays a key and central role in their development. Platelets are the mediators of hemostasis at sites of vascular injury, but they also mediate pathologic thrombosis; activated platelets stimulate thrombus formation in response to rupture of an atherosclerotic plaque or endothelial cell erosion promoting atherothrombotic disease. Recent patent relates to the methods and devices for treating atherosclerosis and to prevent in-stent restenosis or thrombosis. Because of the importance of platelets involvement in the initiation and propagation of thrombosis, antiplatelet drugs have a source of research; in the recent past, new antiplatelet drugs (such as ticagrelor) have been studied and placed in the routine therapy. The aim of this paper is to summarize the pharmacological properties and the clinical characteristics of ticagrelor. </p>","PeriodicalId":20905,"journal":{"name":"Recent patents on cardiovascular drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1574890109666140901150224","citationCount":"1","resultStr":"{\"title\":\"Ticagrelor: a novel drug for an old problem.\",\"authors\":\"Andrea Rognoni,&nbsp;Chiara Cavallino,&nbsp;Alessandro Lupi,&nbsp;Gioel G Secco,&nbsp;Alessia Veia,&nbsp;Sara Bacchini,&nbsp;Roberta Rosso,&nbsp;Sandra Brunelleschi,&nbsp;Francesco Rametta,&nbsp;Angelo S Bongo\",\"doi\":\"10.2174/1574890109666140901150224\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Cardiovascular disease and in particular, acute coronary syndromes are one of the principle causes of death in the industrialized countries. In the setting of acute coronary syndromes (both ST - segment or non ST - segment elevation myocardial infarction), platelets aggregation plays a key and central role in their development. Platelets are the mediators of hemostasis at sites of vascular injury, but they also mediate pathologic thrombosis; activated platelets stimulate thrombus formation in response to rupture of an atherosclerotic plaque or endothelial cell erosion promoting atherothrombotic disease. Recent patent relates to the methods and devices for treating atherosclerosis and to prevent in-stent restenosis or thrombosis. Because of the importance of platelets involvement in the initiation and propagation of thrombosis, antiplatelet drugs have a source of research; in the recent past, new antiplatelet drugs (such as ticagrelor) have been studied and placed in the routine therapy. The aim of this paper is to summarize the pharmacological properties and the clinical characteristics of ticagrelor. </p>\",\"PeriodicalId\":20905,\"journal\":{\"name\":\"Recent patents on cardiovascular drug discovery\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2174/1574890109666140901150224\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Recent patents on cardiovascular drug discovery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1574890109666140901150224\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent patents on cardiovascular drug discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1574890109666140901150224","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

心血管疾病,特别是急性冠状动脉综合征是工业化国家的主要死亡原因之一。在急性冠状动脉综合征(ST段或非ST段抬高型心肌梗死)的情况下,血小板聚集在其发展中起着关键和核心作用。血小板是血管损伤部位的止血介质,但它们也介导病理性血栓形成;当动脉粥样硬化斑块破裂或内皮细胞侵蚀促进动脉粥样硬化性血栓形成时,活化血小板刺激血栓形成。最近的专利涉及治疗动脉粥样硬化和预防支架内再狭窄或血栓形成的方法和装置。由于血小板参与血栓形成的发生和传播的重要性,抗血小板药物有研究的来源;近年来,研究了新的抗血小板药物(如替格瑞洛)并将其纳入常规治疗。本文就替格瑞洛的药理特性及临床特点作一综述。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Ticagrelor: a novel drug for an old problem.

Cardiovascular disease and in particular, acute coronary syndromes are one of the principle causes of death in the industrialized countries. In the setting of acute coronary syndromes (both ST - segment or non ST - segment elevation myocardial infarction), platelets aggregation plays a key and central role in their development. Platelets are the mediators of hemostasis at sites of vascular injury, but they also mediate pathologic thrombosis; activated platelets stimulate thrombus formation in response to rupture of an atherosclerotic plaque or endothelial cell erosion promoting atherothrombotic disease. Recent patent relates to the methods and devices for treating atherosclerosis and to prevent in-stent restenosis or thrombosis. Because of the importance of platelets involvement in the initiation and propagation of thrombosis, antiplatelet drugs have a source of research; in the recent past, new antiplatelet drugs (such as ticagrelor) have been studied and placed in the routine therapy. The aim of this paper is to summarize the pharmacological properties and the clinical characteristics of ticagrelor.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信